Endocrine Society Applauds CMS on CGM Coverage

The Endocrine Society praised the decision to extend access to therapeutic continuous glucose monitors (CGMs) to older Americans on intensive insulin therapy for diabetes.

The Centers for Medicare & Medicaid Services (CMS) announced new coverage criteria for CGM devices Thursday. The guidance states that all Medicare individuals who have type 1 or type 2 diabetes and who use intensive insulin therapy can access therapeutic CGM devices (i.e. Dexcom G5) to monitor their blood glucose levels.

For many years, the Society has advocated to expand coverage for CGMs to the Medicare population. The Society is pleased with the new coverage criteria and looks forward to continuing work with CMS to ensure patients have access to these lifesaving tools.

In its Clinical Practice Guideline on diabetes technology issued in September 2016, the Society recommended CGMs as the gold standard of care for adults with type 1 diabetes. Continuous glucose monitors (CGMs) are primarily used to help in the management of type 1 diabetes, although the devices also can be useful for people with type 2 diabetes, particularly those at risk for severe hypoglycemia.
CGMs measure glucose levels in the fluid between the body’s cells every few minutes throughout the day and night. The technology can tell the user whether glucose levels are rising or falling, and monitor trends from the past several hours. The devices also feature alarms to warn users when glucose levels are too high or too low.

Studies of CGMs have shown that individuals with type 1 diabetes are able to maintain better control of their blood sugar without increasing episodes of hypoglycemia when blood glucose levels drop to dangerously low levels, compared to those who self-monitor blood glucose with periodic fingersticks.

You may also like

  • VIDEO: Exposure to High-Fat Diet In Utero Reprograms Liver, Leads to Metabolic Disease

    In utero exposure to a high-fat diet reprograms the liver, leads to long-term gene dysregulation, and ultimately to metabolic disease, according to the results of an animal study recently published in Endocrinology. Researchers led by Maureen J. Charron, PhD, of Albert Einstein College of Medicine in the Bronx, N.Y., point out that it’s already known…

  • Endocrine Society Joins JDRF’s Coverage2Control Campaign

    The Endocrine Society has signed on as a partner to JDRF’s Coverage2Control campaign, calling on insurance companies to provide better health coverage for the 1.25 million Americans living with type 1 diabetes. Coverage2Control, launched in May, has the support of more than 52,000 people who have signed JDRF’s petition urging insurance companies to provide coverage…